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Introduction 
Oral  route  is  the  simplest  and  easiest  way  for  drug 
administration  because  of  the  greater  stability,  smaller 
bulk  and  easy  production  process.  Drugs  with  low 
aqueous solubility have low dissolution rates and hence 
suffer from poor oral bioavailability. The absorption rate 
of poorly  water  soluble  drugs,  formulated  as  an  orally 
administered  solid  dosage  form,  is  controlled  by  their 
dissolution  rate  in  the  fluid  at  the  absorption  site. 
Consequently  poor  solubility  results  in  low 
bioavailability,  increase  in  the  dose,  large  inter-  and 
intra-subject variation and large variations in blood drug 
concentrations  under  fed  versus  fasted  conditions. 
Enhancement  of  solubility  and  dissolution  rate  is  a 
challenging  task  in  drug  development.
1-5  Absorption 
problem  occur  if  the  aqueous  solubility  is  less  than 
1mg/mL.  Sirolimus  (rapamycin,  SRL)  is  a  lipophilic 
macrocyclic lactone with immunosuppressive properties. 
SRL shows poor water solubility (2.6 µg/mL) and slow 
dissolution rate so that dissolution of the drug is the rate 
limiting step for its absorption. Low solubility of SRL in 
biological  fluids  results  in  poor  bioavailability  (17%) 
after oral administration. This intrinsic physicochemical 
property  of  SRL  and  its  low  chemical  stability,  limits 
bioavailability and further drug development.
6-10 Then it 
is  important  to  improve  the  oral  bioavailability  of  this 
drug  by  improving  its  solubility  and  dissolution  rate. 
Various techniques were used to improve the dissolution 
rate  of  poorly  water  soluble  drugs  including 
micronization,  solubilization,  salt  formation, 
complexation with polymers, physical form change, use 
of  pro-drug  and  drug  derivatization,  addition  of 
surfactants,  formation  of  inclusion  complexes  with 
cyclodextrin,  formation  of  amorphous  drug,  cosolvent 
approach  and  the  formation  of  solid  dispersions  (SDs) 
with hydrophilic carriers.
4,11-19 Solid dispersion is defined 
as dispersion of one or more active ingredients in an inert 
carrier  or  matrix  at  solid  state  prepared  by  melting, 
solvent,  or  melting-solvent  method.  Reduction  or 
absence  of  aggregation  and  agglomeration,  increasing 
wettability,  obtaining  a  homogeneous  distribution  of  a 
small quantity of drug in a solid state may also contribute 
to increase in dissolution rate. Molecular dispersion of 
the drug in polymeric carriers may lead to particle size 
reduction and surface area enhancement, which result in 
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Abstract 
Purpose:  The  aim  of  the  present  investigation  was  preparation  and  characterization  of 
sirolimus  solid  dispersions  by  solvent  evaporation  technique  to  improve  its  dissolution 
properties. 
Methods: Polyvinylpyrrolidone (PVP), Poloxamer 188 and Cremophore RH40 were used to 
prepare  the  solid  dispersions  of  sirolimus.  In  vitro  dissolution  study  using  USP  type  I 
apparatus, were  performed  in distilled  water  (containing  SLS 0.4%)  for  pure  sirolimus, 
physical mixtures, Rapamune and prepared solid dispersions. The characterization of solid 
dispersions  was  performed  using  Fourier  Transform  Infrared  (FTIR)  Spectroscopy  and 
Differential Scanning Calorimetry (DSC).  
Results: More than 75% of sirolimus was released within 30 minutes from all prepared 
solid dispersions. The dissolution rate of all prepared solid dispersion powders were more 
than  physical  mixtures.  The  absence  of  sirolimus  peak  in  the  DSC  spectrum  of  solid 
dispersions indicated the conversion of crystalline form of sirolimus into amorphous form. 
The results from FT-IR spectroscopy showed that there was no significant change in the 
FT-IR spectrum of solid dispersions indicating absence of well-defined interaction between 
drug and carriers.  
Conclusion: It was concluded that solid dispersion method, using PVP, Poloxamer 188 and 
Cremophore RH40 can improve dissolution rate of sirolimus.   
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improvement in dissolution rate. Stabilization of unstable 
drugs  is  another  advantage  of  solid  dispersions.
2,20-26 
Polymers  which  are  often  used  in  SDs  include 
polyethylene  glycols,  polyvinylpyrrolidone  (PVP), 
Eudragits,  Gelucires,  Labrasol,  Cremophore, 
Poloxamers,  Gums,  Mannitol,  Urea  and  Cellulose 
derivatives.  In  the  preparation  of  solid  dispersions, 
solvent evaporation is the main process with large scale 
production  possibilities.  In  many  studies  the  solvent 
evaporation  approach  using  different  evaporation 
methods  was  reported.  These  methods  include  rotary 
evaporation, slow evaporation on a hot plate, evaporation 
under  a  stream  of  nitrogen,  spin  evaporation,  spray 
drying, and the precipitation of solid dispersions using a 
super  critical  fluid.
17,23,24,27-30  The  solid  dispersion 
technique has often proved to be the most successful in 
improving the  dissolution  and bioavailability  of  poorly 
soluble, active pharmaceutical ingredients because  it  is 
simple, economical and advantageous. The objective of 
the  present  investigation  was  to  prepare  SRL  solid 
dispersions  to  improve  the  solubility  of  SRL,  utilizing 
three  polymers,  Poloxamer  188,  Polyvinylpyrrolidone 
and Cremophore RH40. 
 
Materials and Methods 
Materials 
Sirolimus  was  purchased  from  Poli  Company  (Lazio, 
Italy).  Rapamune  tablets  were  prepared  from  Wyeth 
Pharmaceuticals  Company  (Dublin,  Ireland).  Lactose, 
Avicel and Ac-di-sol were obtained from DMV (Veghel, 
Netherland). Magnesium stearate,  Polyvinylpyrrolidone, 
Cremophore RH40, Poloxamer 188, Tocopheryl acetate, 
PEG  6000,  Sodium  lauryl  sulphate,  Aerosil,  Mannitol, 
Ammonium acetate and Isopropyl alcohol were prepared 
from Merck Company (Darmstadt, Germany). 
 
Preparation of physical mixtures (PMs) 
Physical mixtures were prepared according to the carrier 
composition  presented  in  Table  1.  Accurately  weighed 
quantities of drug (1 mg), excipients (Lactose: 175 mg, 
Aerosil:  0.4  mg,  PEG  6000:  5  mg,  Ac-di-sol:  10  mg, 
Stearate  magnesium:  1  mg,  Tocopheryl  acetate:  1  mg) 
and  carrier  were  taken  in  a  glass  bottle  and  mixed 
thoroughly for 5 min by triturating. The resulted product 
was stored in desiccator to carry out further analysis. 
 
Table 1. Carrier composition of prepared formulations. 
Formulation 
code 
PVP 
(mg) 
Poloxamer 
188 (mg) 
Cremophore 
RH40 (mg) 
1  0  14  4 
2  18  0  0 
3  4  13  1 
4  13  4  1 
5  14  0  4 
6  8  8  2 
7  11  4  3 
8  0  18  0 
9  4  11  3 
 
Preparation of solid dispersion formulations 
Solid dispersions of SRL were prepared by the solvent 
evaporation  method.  Accurately  weighed  quantities  of 
SRL  and  the  respective  dispersion  carrier(s)  (Table  1) 
were  transferred  into  a  sufficient  quantity  of  isopropyl 
alcohol to dissolve the ingredients. The mixture was then 
added  to  the  blend  of  excipients  according  to  the 
geometrical dilution method. The obtained granules were 
kept at room temperature for 24 hrs for drying followed 
by sieving (mesh no. 18). The prepared solid dispersions 
were stored in desiccator for further analysis. 
 
Dissolution studies 
The in vitro dissolution study was conducted for physical 
mixture powders, SDs and Rapamune (as an innovator’s 
product and standard formulation) using USP dissolution 
apparatus  I.  Samples  equivalent  to1  mg  of  SRL  were 
added  to  500  mL  of  distilled  water  (containing  SLS 
0.4%)  which  was  maintained  at  37.0  ±  0.5  °C  and 
stirration rate of 100 rpm. An aliquot of 5 mL sample 
was withdrawn at 10, 20, 30, 45, 60 and 120 minutes.
31 
An  equal  volume  of  fresh  dissolution  medium  was 
replaced  immediately  to  keep  the  constant  volume  of 
dissolution  medium.  The  filtered  samples  of  SRL 
(through  Whatmann  filters)  were  assayed  using  our 
previously  developed  RP-HPLC  method  at  278  nm  . 
Calibration curve was constructed in the range of 125-
2000  ng/mL  (r
2=0.9992).  Three  replicates  of  each 
dissolution test were carried out.
32 
 
Fourier Transform Infrared (FTIR) spectroscopy 
The  IR  spectra  of  pure  drug,  excipients,  physical 
mixtures and solid dispersions were recorded using FTIR 
spectrophotometer  (Bomem,  Otava,  Canada).  Sample 
preparation was involved, mixing the sample thoroughly 
with  potassium  bromide  in  the  ratio  of  1:10  (Sample: 
KBr) and pressing under 160 KPa pressure. The scanning 
range was 4000 to 500 cm
-1.  
 
Differential scanning calorimetry (DSC) 
The DSC thermograms of pure drug, carriers, physical 
mixtures  and  solid  dispersions  were  recorded  using 
differential  scanning  calorimeter  (Shimadzu  DSC-60, 
Japan). Five mg of each sample was heated in a sealed 
aluminum pan from 30 °C to 270 °C at a heating rate of 
20 °C/min. 
 
Results and Discussion 
In Vitro dissolution studies 
In vitro release studies revealed that there was marked 
increase  in  the  dissolution  rate  of  SRL  from  all  solid 
dispersion  formulations  when  compared  to  physical 
mixtures. From the in vitro drug release profiles (Figure 
1), it is clear that all solid dispersions released more than 
76%  of  containing  drug  during  30  min,  whereas  the 
released  drug  from  Rapamune  tablets  and  the  physical 
mixtures  was  found  to  be  67%  and  54%  in  30  min 
respectively. However after 120 min, the released drug 
from  Rapamune  was  higher  than  all  solid  dispersion  
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formulations.  In  the  case  of  unprocessed  drug  only 
approximately 7% was dissolved at 30 minutes. The in 
vitro  drug  release  profiles,  also  demonstrated  that 
formulation F3 and F7 containing all of three carriers, 
showed higher dissolution rate compared with other SD 
formulations. This may be attributed to the increase in 
drug wettability, reduction in particle size, conversion to 
amorphous form and solubilization of the drug due to the 
presence of hydrophilic carriers. From Figure 1 it is also 
clear  that  physical  mixture  showed  an  improvement  in 
dissolution rate as compared to pure drug but not such an 
extent as by solvent evaporation technique as shown in 
the  same  figure.  The  dissolution  rate  enhancement  for 
physical mixture (60±2.71% and 82.3±2.03% in 60 and 
120 min respectively) was possibly due to close contact 
of  the  drug  with  hydrophilic  polymer  and  surfactants 
brought  about  by  the  dry  mixing  process.  This  could 
result in increased dispensability and wettability of the 
drug leading to enhanced dissolution rate of SRL. In fact 
as  the  soluble  carriers  dissolve  in  the  medium,  the 
insoluble drug gets exposed to the medium as very fine 
particles resulting in rapid dissolution. To find out the 
most  effective  carrier  and  the  best  combination  of 
carriers  to  enhance  release  rate  of  SRL  from  solid 
dispersion  formulations,  further  research  should  be 
performed.  
 
 
Figure 1. Comparative in vitro dissolution profiles of solid dispersions (F1-F9), physical mixture (PM) and Rapamune. 
 
Fourier Transform Infrared spectroscopy  
IR  spectroscopic  analysis  provides  information  on 
chemical  bonding,  functional  groups  and  presence  or 
absence  of  changes  in  the  crystalline  structure  of  a 
compound. Spectra obtained using infrared spectroscopy 
allows to determine physical and chemical properties of 
the  material  by  recording  frequency  of  vibrations  that 
correlate  with  common  atomic  bonds.  Interactions 
observed between the solid dispersion components such 
as  physical  adsorption  phenomenon,  an  effect  of 
electrostatic forces, hydrogen bond and van der Waals 
interactions are in general reversible, while the chemical 
interactions,  including  ion  exchange,  protonation  and 
complexation  are  irreversible  changes.
18,29,33-36  Changes 
in the IR spectrum confirm presence of these interactions 
and are recorded as new bands, bands disappearing,  a 
shift  or  widening  of  the  existing  bands  as  well  as  a 
change  in  their  intensity.  Figure  2  shows  the  FTIR 
spectra  of  pure  SRL,  physical  mixture  of  SRL  with 
Poloxamer 188 and respective solid dispersions of SRL 
with Poloxamer 188 and PVP. The characteristic peaks 
of SRL (1636 cm
-1, 1717 cm
-1, 2950 cm
-1), PVP (1669 
cm
-1, 3700 cm
-1), Poloxamer 188 (3400 cm
-1, 1110 cm
-1, 
3400 cm
-1) and physical mixture revealed that there were 
no differences in the positions of the absorption bands in 
physical  mixture  indicating  absence  of  any  interaction 
between  SRL  and  carriers  in  simple  mixing  process. 
Spectrum  of  solid  dispersion  prepared  by  PVP  also 
didn’t represent any interaction. A positive shift in peak 
at  1717  cm
-1 to  1720  cm
-1  and
 elimination  of  peak  at 
3400  indicate  formation  of  hydrogen  bound  between 
C=O group of SRL and O-H group of Poloxamer 188. 
However since no changes are seen in other drug bands, 
therefore  the  symmetry  of  drug  molecule  in  solid 
dispersion prepared with Poloxamer 188 is the same as 
pure drug.  
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Figure  2.  Top:  FTIR  spectra  of  pure  SRL  (A),  PVP  (B), 
physical mixture (C) and solid dispersion (D), Bottom: SRL (A), 
Poloxamer 188 (B), physical mixture (C) and solid dispersion 
(D). 
 
Differential scanning calorimetry  
Thermal analysis consists in measurement of changes 
in  selected  physical  parameters  of  a  substance  when 
heated  under  conditions  of  a  linear  temperature 
increase. These changes are recorded as a function of 
time or temperature. DSC is considered to be a modern 
and  accurate  technique  used  in  solid  dispersion 
analysis. DSC enables the quantitative detection of all 
processes in which energy is required or produced (i.e., 
endothermic  or  exothermic  phase  transformations).  It 
allows exploring the process of melting, crystallization, 
evaporation,  phase  equilibriums,  sublimation,  glassy 
and  polymorphic  transformations,  dehydration, 
isomerization,  adsorption  and  substance 
degradation.
25,27,37,38  The  thermal  behavior  of  the 
prepared  solid  dispersions  was  studied  by  DSC.  The 
DSC thermograms for pure SRL, PVP, their PM and 
SDs are shown in Figure 3. The pure SRL showed two 
endothermic  peaks  at  191.35  °C  and  205.27  °C 
indicating  crystallinity  of  SRL.  Poloxamer  188 
exhibited  an  endothermic  melting  peak  at  55  °C. 
Exhibition of a wide peak in the thermogram of PVP at 
90-140  °C,  demonstrates  dehydration  of  PVP  in  that 
range  of  temperature.  Disappearance  of  endothermic 
peaks of SRL in the thermogram of solid dispersions 
prepared  by  Poloxamer  188  and  PVP  represents 
changing  of  crystalline  form  of  SRL  to  amorphous 
form in the solid dispersions. Absence of these peaks in 
physical mixture may be due to the low concentration 
of SRL in PM or melting of SRL in Poloxamer 188 
during the heating process. 
 
Conclusion 
The study revealed that optimum levels of hydrophilic 
carriers  ensure  a  quick  and  complete  dissolution  of 
SRL  from  solid  dispersions  which  are  used  in  oral 
pharmaceutical  formulations.  The  solid  dispersions 
prepared  with  PVP,  Poloxamer  188  and  Cremophore 
RH40 as carrier using the solvent evaporation method 
improved the dissolution properties of SRL and the in 
vitro dissolution test showed a significant increase in 
the  dissolution  rate  of  solid  dispersions  as  compared 
with  pure  SRL  (P<0.05).  The  mechanism  of 
improvement in the dissolution properties, on the basis 
of characterizations was predicted to be the changes in 
the  crystal  form  to  amorphous  form  of  the  drug 
molecules  in  the  solid  dispersions  and  wettability 
property  of  carriers.  The  DSC  thermogram  indicated 
that  crystallinity  of  the  drug  was  reduced  in  solid 
dispersion  formulation  with  Poloxamer  188.  Results 
from  IR  spectroscopy  exhibited  that  there  was 
interaction between SRL and Poloxamer 188.  
 
 
Figure 3. DSC thermograms of Poloxamer 188 (A), physical 
mixture of Poloxamer 188 and SRL (B), solid dispersion with 
Poloxamer 188 (C), solid dispersion with PVP (D) , SRL (E) 
and PVP (F).  
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